Lakewood-Amedex Signs Strategic Advisory Agreement With H.C. Wainwright & Co.

SARASOTA, Fla., Oct. 9, 2013 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has entered into a strategic advisory agreement with H.C. Wainwright & Co., LLC ("Wainwright").

Pursuant to this agreement, Wainwright will assist Lakewood-Amedex in exploring various licensing, M&A, and other strategic endeavors for both existing pipeline products as well as the company's platform technology within the current competitive landscape.

Lakewood-Amedex President and CEO, Steve Parkinson, remarked, "We are excited to be working with H.C. Wainwright & Co., LLC, a well-known and highly respected New York investment bank.  As we prepare to advance our lead bisphosphocin, Nu-2, into clinical trials, we believe that this is an opportune time to engage experienced advisors to help us explore and maximize the value of potential collaborations and relationships with other firms and potential investors in the space."

About Bisphosphocins™:

Bisphosphocins are new class of broad spectrum antimicrobial with a unique mechanism of action that results in rapid bacterial cell death.  There is currently no known mechanism of resistance to the bisphosphocin class which have been proven effective in vitro against over 70 strains of bacteria including, gram positive, gram negative, NDM-1 carrying, and an array of antibiotic resistant strains.  Bisphosphocins have demonstrated efficacy in preclinical models of lung, burn wound, and surgical infections and are being developed to treat a number of serious bacterial infections.  The two lead compounds, designated Nu-2 and Nu-3 are being developed in topical and intravenous formulation to treat acute bacterial skin and skin structure infections, infected diabetic ulcers, ventilated assisted pneumonia, and chronic and complicated urinary tract infections.

About Lakewood-Amedex Inc.

Lakewood-Amedex is a privately held biopharmaceutical company developing a broad portfolio of anti-infective products, including first-in-class anti-bacterial compounds, orally available nanoRNA therapeutics for acute and chronic diseases such as arthritis, inflammation, cancer, influenza, and hepatitis, and a fully human monoclonal antibody for HUS.  The Company's products and technology are covered by an extensive patent portfolio consisting of 40 granted and/or issued patents and 25 pending patent applications filed on a worldwide basis covering all major pharmaceutical markets.  The Company's lead therapeutic candidate is a novel synthetic broad spectrum anti-bacterial proven to be effective in killing a wide range of gram-positive, gram-negative, and antibiotic-resistant bacteria and is expected to enter the clinic in Q1 2014.

About H.C. Wainwright & Co.

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions.  The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets.  According to Sagient Research Systems, the team has been ranked the number one Placement Agent in terms of the aggregate number of PIPE and RD transactions cumulatively since 1998.  H.C. Wainwright was established in 1868 and is headquartered in New York City.

This press release contains forward-looking statements that can be identified by terminology such as "expects", "potential", "suggests", "may", "will" or similar expressions.  Such forward-looking statements regarding our business, which are not historical facts, are "forward-looking statements" that involve risk and uncertainties, which could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements.  Actual results may differ materially from statements made as a result of various factors, including, but not limited to sufficiency of cash to fund the Company's planned operations, risk associated with inherent uncertainty of product research and development, risk of protecting proprietary rights and competition.  Forward-looking statements speak only as to the date they are made.  The Company does not undertake to update forward-looking statements to reflect the circumstances or events that occur after the date the forward-looking statements are made.

Contacts:
Steve Parkinson
President and CEO
Lakewood-Amedex Inc.
(941) 359-0510 / 225 5859
[email protected]

SOURCE Lakewood-Amedex Inc.